Сравнение

Enfuvirtid vs. Linaclotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

159519-65-0

851199-59-2

Молекулярная масса

4491.88 g/mol

1526.74 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Enfuvirtid	Linaclotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Enfuvirtid and Linaclotid?: Enfuvirtid is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Linaclotid?: The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Linaclotid in Germany and the United States?: Германия: Enfuvirtid — Рецептурный, Linaclotid — Рецептурный. США: Enfuvirtid — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Linaclotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Enfuvirtid and Linaclotid?

Enfuvirtid is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Linaclotid?

The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Linaclotid in Germany and the United States?

Германия: Enfuvirtid — Рецептурный, Linaclotid — Рецептурный. США: Enfuvirtid — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.